Chandra Bhagat Pharma Ltd (CBPL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Chandra Bhagat Pharma Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Samir Ramkant Dave
Acquisition/ Disposal of Shares · 27 Oct 2026, 4:27 pm
Samir Ramakant Dave Acquires 5.66% Stake in Chandra Bhagat Pharma Samir Ramakant Dave acquired 8,00,000 convertible warrants in Chandra Bhagat Pharma Limited via a preferential issue allotted on 22nd Oct'26. The acquisition represents 5.66% of the company's total diluted share and voting capital post-conversion. Prior to this allotment, the acquirer held nil shares. Following the preferential issue and assuming full warrant conversion, Chandra Bhagat Pharma's total diluted equity base expands from 75,45,056 shares to 1,41,45,056 equity shares of face value Rs. 10 each.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Chintan Vijay Makhecha
Acquisition/ Disposal of Shares · 27 Oct 2026, 4:19 pm
Chintan Vijay Makhecha Acquired Convertible Warrants in Chandra Bhagat Pharma Chintan Vijay Makhecha, a non-promoter acquirer, disclosed the acquisition of 8,00,000 convertible warrants in Chandra Bhagat Pharma Ltd via a preferential allotment dated 22nd Oct'26. The allotted warrants represent a 5.66% stake on a fully diluted share capital basis. Prior to this allotment, the acquirer held zero shares or voting rights in the company. Following the issue, the company's total diluted equity capital stands at 1,41,45,056 shares of face value Rs. 10 each, up from 75,45,056 shares pre-acquisition.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hemant Chandravadan Bhagat & PACs
Acquisition/ Disposal of Shares · 26 Oct 2026, 6:58 pm
Chandra Bhagat Pharma Allots 50 Lakh Convertible Warrants to Promoter Group Chandra Bhagat Pharma Limited's promoter group was allotted 50,00,000 convertible warrants via a preferential issue on 22nd Oct'26. Prior to the allotment, the promoter and PAC group held 55,09,056 equity shares, representing 73.02% of voting capital and 38.95% on a diluted basis. Following the warrant allotment, their total holding stands at 1,05,09,056 shares/warrants, elevating their post-conversion diluted shareholding to 74.29% across a total diluted share capital of 1,41,45,056 equity shares of face value Rs. 10 each.
Please find attached disclosure under Reg 30 of SEBI (LODR) Regulations, 2015 for your reference.
Others (Uncategorized) · 22 Oct 2026, 5:59 pm
Chandra Bhagat Pharma Approves Allotment of 66 Lakh Preferential Convertible Warrants Chandra Bhagat Pharma Limited's Board has approved the preferential allotment of 66,00,000 convertible warrants at an issue price of Rs. 44 each (face value Rs. 10) to nine promoter and non-promoter investors. The company received an upfront consideration of Rs. 7.26 cr. Each warrant is convertible into one equity share (1:1 ratio) within 18 months from allotment upon receipt of the remaining consideration. Post-conversion, promoters and promoter group entities will hold the majority, while non-promoters Samir Dave and Chintan Makhecha will each hold 5.66%.
Certificate for Non_Applicability of Corporate Governance Certificate for the quarter ended 30th September, 2026.
Others (Uncategorized) · 21 Oct 2026, 8:54 pm
Chandra Bhagat Pharma Non-Applicability of Corporate Governance Report Chandra Bhagat Pharma Ltd confirmed the non-applicability of SEBI corporate governance reporting requirements for the quarter ended 30th Sep'26. Under Regulation 15 of SEBI (LODR) Regulations, 2015, companies listed on the SME Exchange are exempt from submitting compliance reports under Regulations 17–27 and related provisions. Consequently, the company is not required to submit a Corporate Governance Report to the BSE for the specified period.
The Company has informed the stock exchange regarding receipt of In-Principle approval for issue of shares on preferential basis.
Others (Uncategorized) · 13 Oct 2026, 6:01 pm
Chandra Bhagat Pharma Receives In-Principle Approval for Preferential Issue Chandra Bhagat Pharma Limited received in-principle approval from BSE on 12th Oct'26 for a preferential issue under Regulation 28(1) of SEBI LODR Regulations. The approval covers 66,00,000 warrants convertible into 66,00,000 equity shares of face value Rs. 10 each. The securities will be issued to promoter and non-promoter groups at a floor price of Rs. 44 per share, subject to post-issue formalities, statutory compliances, and listing applications within twenty days from allotment.
Disclosure under regulation 30 for resignation of Company Secretary & Compliance Officer.
Change in Management · 01 Oct 2026, 3:06 am
Chandra Bhagat Pharma Announces Resignation of Company Secretary Rajani Dawani Chandra Bhagat Pharma Limited announced that Ms. Rajani Dawani has resigned from her position as Company Secretary and Compliance Officer (Key Managerial Personnel) of the company. The resignation is effective from the closing hours of 30th Sep'26, as she departs to pursue external opportunities and due to pre-occupancy in other assignments.
Declaration of Voting Result along with Scrutinizer Report of Annual General Meeting of the company.
Annual General Meeting · 03 Sept 2026, 11:32 pm
Gist of the Proceeding of the 23rd Annual General Meeting (''AGM'') of the Company held on Tuesday, September 01, 2026.
Annual General Meeting · 01 Sept 2026, 11:41 pm
Please find attached the corrigendum of AGM notice.
Annual General Meeting · 20 Aug 2026, 8:48 pm
Please find attached the notice of shareholders meeting scheduled on 1st September, 2026.
Annual General Meeting · 06 Aug 2026, 9:47 pm
Annual Report 2025-26
Others (Uncategorized) · 06 Aug 2026, 9:40 pm
Chandra Bhagat Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Fund raising through ....
Intimation · 30 Jul 2026, 7:43 pm
Chandra Bhagat Pharma Board to Consider Fundraising via Preferential Issue Chandra Bhagat Pharma has scheduled a Board Meeting for 5th Aug'26 to consider several key proposals. The agenda includes an increase in the authorized share capital and a plan for fundraising. The fundraising will be explored through a preferential allotment of equity shares, convertible warrants, or other instruments for cash or other consideration. The board will also fix the date for an Extra Ordinary General Meeting (EOGM) to seek shareholder approval. The trading window is closed from 30th Jul'26 until 48 hours after the meeting.
Non-applicability of Corporate Governance Report
Others (Uncategorized) · 22 Jul 2026, 1:55 am
Chandra Bhagat Pharma Exempted from Corporate Governance Reporting for Q1FY27 Chandra Bhagat Pharma Limited (BSE: 542934) has confirmed the non-applicability of corporate governance provisions for the quarter ended 30th Jun'26. Citing SEBI's Regulation 15 (LODR), the company is exempt as it is listed on the SME Exchange. Consequently, it is not required to submit the corresponding Corporate Governance Report for the period. The notification was filed on 18th Jul'26.
Financial Result for the period ended 31st march 2026.
Financial Result · 26 May 2026, 12:09 am
Chandra Bhagat Pharma Posts Strong FY26 Results with Unmodified Audit Opinion Chandra Bhagat Pharma reported a significant rise in FY26 profitability, with net profit after tax reaching ₹304.61 lakhs, a 255% YoY increase from ₹85.78 lakhs. Total income for the year ended 31st Mar'26 grew 29.7% YoY to ₹11,962.50 lakhs. Basic EPS jumped to ₹4.04 from ₹1.14 in FY25. The Board approved the audited results on 25th May'26, which received an unmodified opinion from the statutory auditors. The trading window for insiders will reopen 48 hours after the announcement.
Outcome of Board Meeting held on 25th May 2026 for approval of audited result for year ended 31 march 2026.
Outcome · 25 May 2026, 11:43 pm
Chandra Bhagat Pharma Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 9,073 (+316.2% YoY | +255.1% QoQ) ■ EBITDA: 219 (Loss to Profit YoY | +31.3% QoQ) ■ EBITDA Margin (%): 2.4 (Loss to Profit YoY | -411 bps QoQ) ■ PAT: 260 (+1402.0% YoY | +478.3% QoQ) ■ EPS (INR): 3.44 (+1395.7% YoY | +473.3% QoQ)
Chandra Bhagat Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve audited financial result ....
Intimation · 25 May 2026, 5:30 am
Chandra Bhagat Pharma to Review FY26 Financials on 25 May'26 Chandra Bhagat Pharma Ltd. has scheduled a Board of Directors meeting on 25 May'26. The agenda includes the consideration and approval of the audited financial statements and auditor's report for the half-year and fiscal year ended 31 Mar'26. The meeting will take place at 4:00 PM at the company's registered office in Mumbai. This event is a key catalyst for the stock, with the release of full-year earnings and the accompanying auditor's opinion expected to influence market sentiment.
Certificate for Non-applicability of Corporate Governance.
Others (Uncategorized) · 21 Apr 2026, 8:39 pm
Chandra Bhagat Pharma Claims Exemption from Corporate Governance Reporting Chandra Bhagat Pharma (BSE: 542934) has certified the non-applicability of corporate governance provisions for the quarter ended 31 Mar'26. Per SEBI LODR Regulation 15, the company is exempt as it is listed on the SME Exchange. Therefore, it is not required to submit the quarterly Corporate Governance Report. This exemption also applies to firms with paid-up capital under ₹10 crore and net worth under ₹25 crore, though the company specified its SME listing as the primary reason for the exemption.
Discosure under regulation 30 for opening of branch office.
Others (Uncategorized) · 01 Apr 2026, 9:17 pm
Chandra Bhagat Pharma Opens New UAE Office to Boost Global Expansion Chandra Bhagat Pharma Limited has expanded its international presence by opening a new International Business/Representative Office. The filing states the office is in Dubai, but the certificate of formation indicates a branch in Sharjah Media City Free Zone, established on 31-Mar'26. This strategic move aims to expand the company's global footprint, enhance export opportunities, and strengthen relationships with international clients and partners. The initiative is aligned with the company's strategic growth plans to tap international markets and enhance its global business operations.
Certificate for Non-applicability of Corporate Governance.
Others (Uncategorized) · 21 Jan 2026, 5:57 pm
Chandra Bhagat Pharma Claims Exemption from Corporate Governance Reporting for Q3 FY26 Chandra Bhagat Pharma Limited (BSE: 542934) has notified the exchange on 21 Jan'26 that corporate governance provisions under SEBI LODR regulations are not applicable for the quarter ended 31 Dec'25. The company claims exemption as it is listed on the SME Exchange and its paid-up capital does not exceed ₹10 crore, with net worth not exceeding ₹25 crore as of the last financial year. Consequently, it is not required to submit the corresponding corporate governance report for the period.
Outcome of the Board Meeting held on 13th November, 2025 for approval of un-audited result as on 30th September, 2025.
Financial Result · 14 Nov 2025, 1:19 am
Outcome of the Board Meeting held on 13th November, 2025.
Outcome · 14 Nov 2025, 1:15 am
Chandra Bhagat Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve Un-audited result for ....
Intimation · 13 Nov 2025, 5:30 am
Corporate Governance Disclosure
Others (Uncategorized) · 20 Oct 2025, 10:57 pm
Scrutinizer''s Report.
Annual General Meeting · 01 Oct 2025, 3:45 am